Mid-cap Health Care company Legend Biotech has moved 1.1% so far today on a volume of 444,413, compared to its average of 697,411. In contrast, the S&P 500 index moved -0.0%.
Legend Biotech trades -27.79% away from its average analyst target price of $87.69 per share. The 14 analysts following the stock have set target prices ranging from $76.0 to $100.0, and on average have given Legend Biotech a rating of buy.
Anyone interested in buying LEGN should be aware of the facts below:
-
Legend Biotech has moved 17.0% over the last year, and the S&P 500 logged a change of 17.0%
-
Based on its trailing earnings per share of -2.96, Legend Biotech has a trailing 12 month Price to Earnings (P/E) ratio of -21.4 while the S&P 500 average is None
-
LEGN has a forward P/E ratio of -34.0 based on its forward 12 month price to earnings (EPS) of $-1.86 per share
-
Its Price to Book (P/B) ratio is 8.59 compared to its sector average of None
-
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally.
-
Based in Somerset, the company has 1,700 full time employees and a market cap of $11.54 Billion.